Friday, 26 June 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 26 June 2026
News

Arrotex inks first-to-market deal

Posted 25 June 2026 PM

Arrotex has lost its CEO but the deals keep coming with an exclusive agreement to bring first-to-market prescription eye drops to Australia to treat presbyopia, this time with group CEO Dennis Bastas doing the talking.

Vizz eye drops, 1.44% Aceclidine, is the only product of US-based Lenz, and is sold in the US for $115 (US$79) a month. Arrotex has nabbed the exclusive commercialisation rights in Australia and New Zealand to treat presbyopia.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (17)

Access & Reimbursement (2)

Clinical & Medical, R&D (7)

Regulatory, Pharmacovigilance & QA (6)

Other (12)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.